NCT07125209 Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
| NCT ID | NCT07125209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 18 participants |
| Start Date | 2026-04-28 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 18 participants in total. It began in 2026-04-28 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * Pathological diagnosis of suspected epithelial ovarian cancer; of note, patients with suspected epithelial ovarian cancer who are pending a pathological diagnosis/biopsy may be enrolled onto the study ahead of their biopsy. If the biopsy result is later inconsistent with epithelial ovarian cancer, they will be removed from the study and replaced * Planned to received neoadjuvant chemotherapy with carboplatin and paclitaxel; alternatives to these agents including abraxane, docetaxel, cisplatin may be used if patients have a chemotherapy reaction or otherwise cannot receive carboplatin and paclitaxel per usual standard of care * Patients may be receiving bevacizumab and may receive PARP inhibitors as a maintenance treatment; those receiving any other targeted therapy will be excluded Exclusion Criteria: * History of diagnosed cognitive impairment, including dementia * History of traumatic brain injury * English is not their primary language * Known hearing or visual impairment not corrected with hearing devices and glasses/contacts * Upper extremity motor impairment that would impact ability to perform the Trail Making Test * Baseline Mini Mental State Exam (MMSE) score less than 18
Contact & Investigator
Lisa Barroilhet, MD
PRINCIPAL INVESTIGATOR
UW Carbone Cancer Center
Frequently Asked Questions
Who can join the NCT07125209 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07125209 currently recruiting?
Yes, NCT07125209 is actively recruiting participants. Contact the research team at supportiveoncology@uwcarbone.wisc.edu for enrollment information.
Where is the NCT07125209 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT07125209 clinical trial?
NCT07125209 is sponsored by University of Wisconsin, Madison. The principal investigator is Lisa Barroilhet, MD at UW Carbone Cancer Center. The trial plans to enroll 18 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.